HB 229

  • Kentucky House Bill
  • 2024 Regular Session
  • Introduced in House Jan 10, 2024
  • House
  • Senate
  • Governor

AN ACT relating to gene therapy.

Abstract

Create a new section of KRS 217.005 to 217.215, the Kentucky Food, Drug, and Cosmetic Act, to define terms; require products that are known to be or could act as gene therapy to be labeled with the words "Potential Gene Therapy Product" or "Gene Therapy Product"; require any entity in the state that produces, sells, or distributes a product in this state with the capacity to infect an individual with a disease or to expose an individual with genetically modified material to provide information upon request on how individuals may be exposed; require informed consent before any entity makes available a product in this state that would act as a medical intervention, vaccine, drug, or genetic modification.

Bill Sponsors (6)

Votes


No votes to display

Actions


Jan 10, 2024

House

introduced in House

House

to Committee on Committees (H)

Bill Text

Bill Text Versions Format
Introduced PDF

Related Documents

Document Format
No related documents.

Sources

Data on Open States is updated periodically throughout the day from the official website of the Kentucky General Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.